NASDAQ
8.23USD
+0.03 (+0.37%)
We have scored 6 news catalysts on Kamada Ltd. (KMDA) over the past 12 months. The biggest single-day move next to one of them came Aug 14, 2026, when KMDA closed +4.4%: “Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet”. Coverage across the window leans positive (average ticker sentiment +0.60). Most of the impact sits in earnings revision trend and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
479.4M
P/E
—
EPS
—
Beta
0.14
52W range
6.5-9.35
Day range
8.18–8.33
Open
8.33
Prev close
8.20
Volume
31.3K
Avg volume
92.9K
Dividend
0.42
IPO
2013-05-31
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Kamada Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Kamada Ltd., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for KMDA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.
